Results 61 to 70 of about 259,075 (330)

Pragmatic randomized controlled trial of long-term psychoanalytic psychotherapy for treatment-resistant depression: the Tavistock Adult Depression Study (TADS) [PDF]

, 2015
This pragmatic randomized controlled trial tested the effectiveness of long-term psychoanalytic psychotherapy (LTPP) as an adjunct to treatment-as-usual according to UK national guidelines (TAU), compared to TAU alone, in patients with long-standing ...
Andrews, Bateman, Beck, Beecham, Beutel, Carvalho, Daban, Driessen, Endicott, Evans, First, Fonagy, Frank, Greden, Hamilton, Hilsenroth, Hollon, Hollon, Huhn, Jones, Keller, Keller, Knekt, Knekt, Kubitz, Lam, Leichsenring, Leichsenring, Luborsky, Maat, McIntyre, McPherson, Milton, Morishita, Moussavi, Muratori, National Institute for Health and Clinical Excellence., Rabe-Hesketh, Rawlins, Reimherr, Rossouw, Shedler, Spijker, Statacorp., Stimpson, Taylor, Taylor, Thomas, Trivedi, Verbeke   +49 more
core   +1 more source

Magnitude of the Placebo Response Across Treatment Modalities Used for Treatment-Resistant Depression in Adults

JAMA Network Open, 2021
Key Points Question What is the placebo effect magnitude in different treatment modalities used for management of patients with treatment-resistant depression? Findings In this systematic review and meta-analysis of 3228 patients with treatment-resistant
Brett D. M. Jones, L. Razza, C. Weissman, Jewel Karbi, Tya Vine, L. Mulsant, A. Brunoni, M. Husain, B. Mulsant, D. Blumberger, Z. Daskalakis   +10 more
semanticscholar   +1 more source

Suicidality in Treatment-Resistant Depression Patients

European Psychiatry, 2023
Introduction Depression and treatment-resistant depression (RD) are associated with suicidal behavior (SB) at a higher rate. Objectives 1) determination prevalence of RD in district outpatient psychiatric сlinics (i.e., dispensaries) and the socio ...
E. B. Lyubov, N. D. Semenova
doaj   +1 more source

Telomere length as a predictor of response to Pioglitazone in patients with unremitted depression: a preliminary study. [PDF]

, 2016
We studied peripheral leukocyte telomere length (LTL) as a predictor of antidepressant response to PPAR-γ agonist in patients with unremitted depression.
Blackburn, E, Epel, E, Lin, J, Lin, KW, Rasgon, N   +4 more
core   +1 more source

Management of Treatment-Resistant Depression: Challenges and Strategies

Neuropsychiatric Disease and Treatment, 2020
Treatment-resistant depression (TRD) is a subset of Major Depressive Disorder which does not respond to traditional and first-line therapeutic options.
Daphne Voineskos, Z. Daskalakis, D. Blumberger   +2 more
semanticscholar   +1 more source

Medicaid spending burden among beneficiaries with treatment-resistant depression. [PDF]

, 2019
AIM: To evaluate Medicaid spending and healthcare resource utilization (HRU) in treatment-resistant depression (TRD). MATERIALS & METHODS: TRD beneficiaries were identified from Medicaid claims databases (January 2010-March 2017) and matched 1:1 with ...
Greenberg, Paul E., Jacques, Philippe, Lefebvre, Patrick, Lejeune, Dominique, Pilon, Dominic, Sheehan, John J., Singer, David, Szukis, Holly   +7 more
core   +1 more source

Maintenance deep transcranial magnetic stimulation sessions are associated with reduced depressive relapses in patients with unipolar or bipolar depression [PDF]

, 2015
Introduction: Deep transcranial magnetic stimulation (dTMS) is a new form of TMS allowing safe stimulation of deep brain regions. The objective of this preliminary study was to assess the role of dTMS maintenance sessions in protecting patients with ...
ANGELETTI, Gloria, BERSANI, FRANCESCO SAVERIO, DEL CASALE, ANTONIO, DI PIETRO, SIMONE, Ferri, Vittoria R., GIRARDI, Paolo, Imperatori, Claudio, KOTZALIDIS, GEORGIOS, Raccah, Ruggero N., RAPINESI, CHIARA, SERATA, DANIELE, Zangen, Abraham   +11 more
core   +2 more sources

Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial

Molecular Psychiatry
Further research is needed to help improve both the standard of care and the outcome for patients with treatment-resistant depression. A particularly critical evidence gap exists with respect to whether pharmacological or non-pharmacological augmentation
G. Papakostas, Madhukar H. Trivedi, Richard C. Shelton, D. Iosifescu, Michael E. Thase, Manish K Jha, S. J. Mathew, C. Debattista, Mehmet e Dokucu, Olga Brawman-Mintzer, Glenn W Currier, W. V. McCall, M. Modirrousta, Matthew Macaluso, A. Bystritsky, Fidel Vila Rodriguez, Erik B. Nelson, Albert Yeung, Anna Feeney, Leslie C MacGregor, Thomas Carmody, Maurizio Fava   +21 more
semanticscholar   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

A model for the management of difficult to treat depression

European Psychiatry, 2021
In this presentation a model for the management of difficult to treat depression (DTD) will be presented based upon a recently published international consensus statement (McAllister-Williams et al. 2020 Journal of Affective Disorders 267:264-282).
H. Mcallister-Williams
doaj   +1 more source